P.222Long term progression in type II spinal muscular atrophy: a retrospective observational study
Eugenio Mercuri(Università Cattolica del Sacro Cuore), Marika Pane(Università Cattolica del Sacro Cuore), Nicola Forcina(Università Cattolica del Sacro Cuore), Simona Lucibello(Università Cattolica del Sacro Cuore), Maria Carmela Pera(Università Cattolica del Sacro Cuore), Lavinia Fanelli(Università Cattolica del Sacro Cuore), Sara Carnicella(Università Cattolica del Sacro Cuore), E. Mazzone(Università Cattolica del Sacro Cuore), Giulia Norcia, Laura Antonaci, Giorgia Coratti, A. Frongia(Università Cattolica del Sacro Cuore), Rita De Sanctis(Humanitas University)
Cited by 0
Related Papers
Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp> uchenne muscular dystrophy
|Annals of Neurology|2015|502
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178